Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Specialty & Advanced Pharmaceuticals
02/23PUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/23SHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
02/23NOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
02/22Seed firms scramble to stop a 'cancer' in Canada's cash crop
RE
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
02/21MERCK : to Invest Additional EUR40 Million in Asia
DJ
02/21Merck to buy virus-based cancer drug firm Viralytics for $394 million
RE
02/21MERCK AND : to Buy Australia's Viralytics for $394 Million
DJ
02/21NOVARTIS : Builds Up R&D -- WSJ
DJ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Stronger European Earnings Augur More M&A, Higher Dividends
DJ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19ASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
DJ
02/18NOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
02/16NOVARTIS : readies to auction U.S. generic pills business - sources
RE
02/16Backstory - Warren Buffett's Valentine's Day surprise for investors
RE
02/16WARREN BUFFETT : Warren Buffett's Valentine's Day surprise for investors
RE
02/16BACKSTORY : Warren Buffett's Valentine's Day surprise for investors
RE
02/16Pot Pharm - Booming Canada weed sector plots next-wave medicines
RE
02/16POT PHARM : Booming Canada weed sector plots next-wave medicines
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
RE
02/15ROCHE : to Acquire Healthcare-Software Company Flatiron for $1.9 Billion
DJ
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15AbbVie to buy back $10 billion of shares, raises dividend
RE
02/15Cyclicals, South Africa-exposed stocks help steady FTSE 100
RE
02/15European shares build on recovery, Airbus shines
RE
02/15SANOFI : Correction to Sanofi Dengue Vaccine Article on Feb. 2
DJ
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial -- Upd..
DJ
02/15MERCK : and Pfizer's Avelumab Fails to Meet Endpoint in Lung Cancer Trial
DJ
02/15Growth formula eludes under-fire Nestle, L'Oreal stake unchanged
RE
02/15Indivior bets on $1 billion anti-addiction shot as legal bill weighs
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15SHIRE PLC SHIRE PLC : Director/Pdmr Shareholding
DJ
02/15BAYER : Syngenta aims to sell bonds within weeks, M&A important - CFO
RE
02/15COLOPLAST A/S : ConvaTec beats low full-year expectations, shares rise
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/15ASTRAZENECA : Says Selumetinib Granted FDA Orphan Drug Status
DJ
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14SHIRE : 4Q Product Sales and Generic Competition in Focus -- Earnings Review
DJ
02/14BAYER : Gets FDA Warning Over Manufacturing Practices at German Site
DJ
02/14SHIRE : 4Q Profit Rises on U.S. Tax Reform
DJ
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 488 M
Debt 2018 22 102 M
Yield 2018 2,66%
P/E ratio 2018 17,64
P/E ratio 2019 15,27
EV / Sales 2018 6,54x
EV / Sales 2019 5,94x
Capitalization 188 B